In short
Onasemnogene Abeparvovec, also known as Zolgensma, is a groundbreaking gene therapy drug being studied in clinical trials for the treatment of Spinal Muscular Atrophy (SMA). These trials aim to assess the long-term safety and effectiveness of the drug in patients who have received it through intravenous (IV) or intrathecal (IT) administration. The studies focus on monitoring adverse events, developmental milestones, motor function, and overall quality of life for patients with SMA over extended periods, ranging from 5 to 15 years.
At a glance
- Drug Name
- Onasemnogene Abeparvovec (Zolgensma)
- Condition Treated
- Spinal Muscular Atrophy (SMA)
- Trial Duration
- Up to 15 years
- Primary Objectives
- Long-term safety and efficacy assessment
- Key Assessments
- Adverse events, motor function, developmental milestones, cognitive function
- Administration Routes
- Intravenous (IV) and Intrathecal (IT)
- Participant Eligibility
- SMA patients previously treated with Onasemnogene Abeparvovec in clinical trials
What is ONASEMNOGENE ABEPARVOVEC?
ONASEMNOGENE ABEPARVOVEC, also known by its brand name Zolgensma, is a groundbreaking gene therapy medication used to treat Spinal Muscular Atrophy (SMA). It is classified as an advanced therapy medicinal product (ATMP) and specifically as an in vivo gene therapy. This means that the treatment is administered directly into the patient's body to modify their genetic material.
How Does It Work?
ONASEMNOGENE ABEPARVOVEC works by delivering a functional copy of the SMN1 gene to the patient's cells. This gene is responsible for producing a protein essential for motor neuron survival. In SMA patients, this gene is missing or defective. The therapy uses a modified virus (AAV9) as a vector to carry the healthy gene into the cells. Once inside, the cells can start producing the necessary protein, potentially improving muscle function and survival in SMA patients.
What Conditions Does It Treat?
ONASEMNOGENE ABEPARVOVEC is specifically designed to treat Spinal Muscular Atrophy (SMA). SMA is a rare genetic disorder that affects muscle strength and movement. There are several types of SMA, including: Spinal muscular atrophy type I (also known as Werdnig-Hoffmann disease) Spinal muscular atrophy type II Spinal muscular atrophy type III (also known as Kugelberg-Welander disease) This treatment is particularly important for infants and young children diagnosed with SMA, as early intervention can significantly impact the course of the disease.
Administration
ONASEMNOGENE ABEPARVOVEC is administered as a one-time intravenous infusion. The medication comes in the form of a solution for infusion, with a concentration of 2 × 10^13 vector genomes/mL. It's important to note that this is a single-dose treatment, meaning patients typically receive only one infusion in their lifetime.
Clinical Trials and Research
Extensive research has been conducted to evaluate the safety and efficacy of ONASEMNOGENE ABEPARVOVEC. Clinical trials have included: Phase 1 trials (AVXS-101-CL-102) Phase 3 trials (AVXS-101-CL302, AVXS-101-CL-303, AVXS-101-CL-304, AVXS-101-CL-306) These trials have involved patients with various types of SMA and have helped establish the treatment's effectiveness and safety profile.
Long-Term Safety and Efficacy
To better understand the long-term effects of ONASEMNOGENE ABEPARVOVEC, ongoing studies are being conducted. These include: A 15-year follow-up study to assess long-term safety, focusing on serious adverse events (SAEs) and adverse events of special interest (AESIs). A study evaluating long-term efficacy through measures such as: Developmental milestones Hammersmith Functional Motor Scale - Expanded (HFMSE) score Revised Upper Limb Module (RULM) Cognitive and language development assessments These studies aim to provide a comprehensive understanding of how the treatment affects patients over time, including their motor function, cognitive development, and overall quality of life.
Potential Side Effects
As with any medical treatment, ONASEMNOGENE ABEPARVOVEC may cause side effects. The long-term studies are closely monitoring for: Changes in vital signs Alterations in physical examination findings Changes in clinical laboratory assessments Cardiac assessment changes Pulmonary function changes and need for ventilatory support Swallowing dysfunction and need for nutritional support It's important for patients and caregivers to discuss potential risks and benefits with their healthcare provider before starting treatment.